Earnings Alerts

Medibank Private (MPL) Earnings: FY Revenue Hits A$8.18 Billion, Net Income A$496.4 Million

  • Revenue Matches Estimates: Medibank Private‘s full-year revenue hit A$8.18 billion, exactly as analysts predicted.
  • Net Income: The company’s net income for the year was A$496.4 million.
  • Dividend: Shareholders will receive a final dividend of A$0.0940 per share.
  • Net Investment Income: Medibank Private achieved a net investment income of A$182.2 million.
  • Underlying Profit: The underlying profit stood at A$570.4 million.
  • Analyst Ratings: The stock has 5 buy ratings, 6 hold ratings, and no sell ratings.

A look at Medibank Private Smart Scores

FactorScoreMagnitude
Value2
Dividend3
Growth4
Resilience4
Momentum4
OVERALL SMART SCORE3.4

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Medibank Private Limited is positioned for a positive long-term outlook based on the Smartkarma Smart Scores assessment. With a Growth score of 4, the company shows promising potential for expansion and advancement in the market. This indicates a strong trajectory for Medibank in terms of future development and revenue growth.

Moreover, Medibank scores well in terms of Resilience and Momentum with scores of 4 each. This suggests that the company is robust and adaptable to market challenges while also displaying strong upward momentum in its operations. These factors bode well for Medibank’s sustained success and competitiveness in the private health care coverage sector.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars